Cutia Therapeutics (HK:2487) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cutia Therapeutics’ CEO and Executive Director, Ms. Zhang Lele, demonstrated her confidence in the company by purchasing 8,000 additional shares with her personal funds, signaling potential growth and stability to shareholders and investors. The company has assured that it maintains the required public float in compliance with Hong Kong’s listing rules, post-purchase. Shareholders are cautioned to exercise prudence when dealing in company shares.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.